Gilly Regev (CEO) & Chris Miller (CSO) are the Co-Founders of Canadian R&D company, SaNOtize Research and Development Corp. Regev earned her PhD in Biochemistry at the Hebrew University of Jerusalem and Miller originally a respiratory therapist, earned his PhD in Experimental Medicine from the University of British Colombia and holds BA in Health Management. Both are exceptional leaders with strong academic foundations, are well published, have biotech start-up experience with decades of expertise in harnessing the core antimicrobial technology, nitric oxide. Since SaNOtize’s 2017 launch, they have successfully led the company from the laboratory, through the clinical regulatory gauntlet, formulation and scaled manufacturing hurdles to the retail shelf. Their lead product, Nitric Oxide Nasal Spray (NONS™), is approved for sale in more than 10 countries and they are now in discussions with regulatory authorities in both Canada and the U.S.
While more work needs to be done, the current research into new delivery platforms for nitric oxide is extremely promising. We hope to see the molecule play an increasingly prominent role in treatment and prevention strategies for common infections – and in so doing help provide greater access to healthcare globally.